Search

Your search keyword '"Zerbi, Caterina"' showing total 17 results
Start Over Author "Zerbi, Caterina"
17 results on '"Zerbi, Caterina"'

1. Molecular characterization of diffuse large B‐cell lymphomas associated with hepatitis C virus infection

Author

Sciarra, Roberta, primary, Merli, Michele, additional, Cristinelli, Caterina, additional, Lucioni, Marco, additional, Zibellini, Silvia, additional, Riboni, Roberta, additional, Furlan, Daniela, additional, Uccella, Silvia, additional, Zerbi, Caterina, additional, Bianchi, Benedetta, additional, Gotti, Manuel, additional, Ferretti, Virginia Valeria, additional, Varraso, Chiara, additional, Fraticelli, Sara, additional, Lazic, Tanja, additional, Defrancesco, Irene, additional, Mora, Barbara, additional, Libera, Laura, additional, Mazzacane, Alessandro, additional, Carpi, Federico, additional, Berliner, Martha, additional, Neri, Giuseppe, additional, Rizzo, Ettore, additional, De Paoli, Federica, additional, Sessa, Fausto, additional, Passamonti, Francesco, additional, Paulli, Marco, additional, and Arcaini, Luca, additional

Published
2024
Full Text
View/download PDF

2. Retrospective investigation of Human Papillomavirus cervical infection and lymphoma incidence: a clinical and pathological evaluation

Author

Gardella, Barbara, primary, Dominoni, Mattia, additional, Pasquali, Marianna Francesca, additional, Gotti, Manuel, additional, Fraticelli, Sara, additional, Lucioni, Marco, additional, Cesari, Stefania, additional, Fiandrino, Giacomo, additional, De Silvestri, Annalisa, additional, Zerbi, Caterina, additional, Lazic, Tanja, additional, Arcaini, Luca, additional, Paulli, Marco, additional, and Spinillo, Arsenio, additional

Published
2024
Full Text
View/download PDF

4. Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi

Author

Gotti, Manuel, primary, Sciarra, Roberta, additional, Pulsoni, Alessandro, additional, Merli, Francesco, additional, Luminari, Stefano, additional, Zerbi, Caterina, additional, Trentin, Livio, additional, Re, Alessandro, additional, Rusconi, Chiara, additional, Viviani, Simonetta, additional, Rossi, Andrea, additional, Cocito, Federica, additional, Botto, Barbara, additional, Meli, Erika, additional, Pinto, Antonello, additional, Dogliotti, Irene, additional, Gini, Guido, additional, Puccini, Benedetta, additional, Ricci, Francesca, additional, Nassi, Luca, additional, Fabbri, Alberto, additional, Liberati, Anna Marina, additional, Merli, Michele, additional, Filippi, Andrea Riccardo, additional, Bonfichi, Maurizio, additional, Zoboli, Valentina, additional, Tartaglia, Germana, additional, Annechini, Giorgia, additional, D’Elia, Gianna Maria, additional, Del Giudice, Ilaria, additional, Alvarez, Isabel, additional, Visentin, Andrea, additional, Pravato, Stefano, additional, Dalceggio, Daniela, additional, Pagani, Chiara, additional, Ferrari, Silvia, additional, Cristinelli, Caterina, additional, Lazic, Tanja, additional, Ferretti, Virginia Valeria, additional, Ricardi, Umberto, additional, and Arcaini, Luca, additional

Published
2023
Full Text
View/download PDF

5. Navigating ‘grey areas’ and challenges during evaluation of transplant eligibility in specific myelofibrosis populations: a perspective on behalf of the Chronic Malignancies Working Party of the EBMT

Author

Polverelli, Nicola, Hernández-Boluda, Juan Carlos, Gagelmann, Nico, Gurnari, Carmelo, Malagola, Michele, Duarte, Fernando Barroso, Funke, Vaneuza A. M., Zerbi, Caterina, and McLornan, Donal P.

Abstract

Significant efforts have been made to effectively select myelofibrosis (MF) patients who can benefit from allogeneic hematopoietic cell transplantation (allo-HCT), the only current cure for MF. The recent EBMT/ELN 2024 recommendations offer valuable guidance for hematologists and transplant physicians. However, several grey areas remain in day-to-day clinical practice regarding the feasibility and optimal preparation for transplantation in patients with this disease. Effective spleen size reduction, often achieved with JAK inhibitors, appears crucial for transplant success. For resistant cases, switching JAK inhibitors, splenectomy, or spleen irradiation may be considered, taking into account patient profiles, treatment availability and center preferences. Managing splanchnic vein thromboses, portal, and pulmonary hypertension is critical as these conditions may affect transplant outcomes. Cytopenias, particularly transfusion-dependent anemia and thrombocytopenia, complicate treatment and impact on outcomes, though new drugs show promise. Comorbidities play a significant role and tools like the Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) and frailty assessments are useful for evaluating transplant risks while allowing the implementation of corrective measures. Especially in low- and medium-income countries where access to novel therapies may be challenging, allo-HCT still represents an attractive therapeutic option for MF. Future directions include integrating new therapeutics into the transplant algorithm and leveraging artificial intelligence for more informed risk assessment, highlighting the need for tailored approaches to improve allo-HCT outcomes in such a setting.

Published
2024
Full Text
View/download PDF

6. P006: Clinical outcome of classical Hodgkin Lymphoma patients receiving systemic anti-lymphoma treatment during SARS-COV-2 positivity: Results from the chemo-covid study on behalf of fondazione italiana linfomi

Author

Rusconi, Chiara, primary, Puccini, Benedetta, additional, Visco, Carlo, additional, Ricci, Francesca, additional, Re, Alessandro, additional, Zilioli, Vittorio R., additional, Zerbi, Caterina, additional, Hohaus, Stefan, additional, Mazzon, Federico, additional, Ciceri, Manuel, additional, Guidetti, Anna, additional, Marasco, Vincenzo, additional, and Rigacci, Luigi, additional

Published
2022
Full Text
View/download PDF

7. P113: Promising results with anti-PD-1 therapy in primary refractory Hodgkin lymphoma: a single-centre report

Author

Zerbi, Caterina, primary, Lazic, Tanja, additional, Sciarra, Roberta, additional, Cristinelli, Caterina, additional, Mazzacane, Alessandro, additional, Carpi, Federico, additional, Ferretti, Virginia Valeria, additional, Gambini, Giulia, additional, Bonfichi, Maurizio, additional, Arcaini, Luca, additional, and Gotti, Manuel, additional

Published
2022
Full Text
View/download PDF

8. Secondary infections worsen the outcome of COVID‐19 in patients with hematological malignancies: A report from the ITA‐HEMA‐COV.

Author

Zappasodi, Patrizia, Cattaneo, Chiara, Valeria Ferretti, Virginia, Mina, Roberto, José María Ferreri, Andrés, Merli, Francesco, Oberti, Margherita, Krampera, Mauro, Romano, Alessandra, Zerbi, Caterina, Ferrari, Jacqueline, Cavo, Michele, Salvini, Marco, Bertù, Lorenza, Stefano Fracchiolla, Nicola, Marchesi, Francesco, Massaia, Massimo, Marasco, Vincenzo, Cairoli, Roberto, and Maria Scattolin, Anna

Subjects
HEMATOLOGIC malignancies, COVID-19, ACUTE myeloid leukemia, TREATMENT effectiveness, INFECTION
Abstract

The impact of secondary infections (SI) on COVID‐19 outcome in patients with hematological malignancies (HM) is scarcely documented. To evaluate incidence, clinical characteristics, and outcome of SI, we analyzed the microbiologically documented SI in a large multicenter cohort of adult HM patients with COVID‐19. Among 1741 HM patients with COVID‐19, 134 (7.7%) had 185 SI, with a 1‐month cumulative incidence of 5%. Median time between COVID‐19 diagnosis and SI was 16 days (IQR: 5–36). Acute myeloid leukemia (AML) and lymphoma/plasma cell neoplasms (PCN) were more frequent diagnoses in SI patients compared to patients without SI (AML: 14.9% vs. 7.1%; lymphoma/PCN 71.7% vs. 65.3%). Patients with SI were older (median age 70 vs. 66 years, p = 0.002), with more comorbidities (median Charlson Comorbidity Index 5 vs. 4, p < 0.001), higher frequency of critical COVID‐19 (19.5% vs. 11.5%, p = 0.046), and more frequently not in complete remission (75% vs. 64.7% p = 0.024). Blood and bronchoalveolar lavage were the main sites of isolation for SI. Etiology of infections was bacterial in 80% (n = 148) of cases, mycotic in 9.7% (n = 18) and viral in 10.3% (n = 19); polymicrobial infections were observed in 24 patients (18%). Escherichia coli represented most of Gram‐negative isolates (18.9%), while coagulase‐negative Staphylococci were the most frequent among Gram‐positive (14.2%). The 30‐day mortality of patients with SI was higher when compared to patients without SI (69% vs. 15%, p < 0.001). The occurrence of SI worsened COVID‐19 outcome in HM patients. Timely diagnosis and adequate management should be considered to improve their prognosis. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

9. Molecular Characterization of Diffuse Large B-Cell Lymphoma Associated to Hepatitis C Virus Infection

Author

Sciarra, Roberta, primary, Cristinelli, Caterina, additional, Merli, Michele, additional, Lucioni, Marco, additional, Zibellini, Silvia, additional, Riboni, Roberta, additional, Ferretti, Virginia Valeria, additional, Uccella, Silvia, additional, Zerbi, Caterina, additional, Bianchi, Benedetta, additional, Furlan, Daniela, additional, Bonfichi, Maurizio, additional, Gotti, Manuel, additional, Varraso, Chiara, additional, Fraticelli, Sara, additional, Defrancesco, Irene, additional, Frigeni, Marco, additional, Lazic, Tanja, additional, Ferrario, Giuseppina, additional, Sessa, Fausto, additional, Passamonti, Francesco, additional, Paulli, Marco, additional, and Arcaini, Luca, additional

Published
2021
Full Text
View/download PDF

10. Systematic screening for SARS-CoV-2 in patients with hematological malignancies on active anticancer treatment in the outpatient setting

Author

Varettoni, Marzia, primary, Mangiacavalli, Silvia, additional, Rattotti, Sara, additional, Cartia, Claudio Salvatore, additional, Cavalloni, Chiara, additional, Rossetti, Franca, additional, Ferretti, Virginia Valeria, additional, Bergamini, Fabio, additional, Trotti, Chiara, additional, Fiorelli, Nicolas, additional, Pagani, Giuseppina, additional, Zerbi, Caterina, additional, Ferrari, Jacqueline, additional, Cristinelli, Caterina, additional, Muzzi, Alba, additional, Marena, Carlo, additional, Baldanti, Fausto, additional, Bruno, Raffaele, additional, and Arcaini, Luca, additional

Published
2021
Full Text
View/download PDF

11. Mutational and immunogenetic landscape of HCV ‐associated B‐cell lymphoproliferative disorders

Author

Defrancesco, Irene, primary, Visentini, Marcella, additional, Zibellini, Silvia, additional, Minafò, Ylenia Aura, additional, Rattotti, Sara, additional, Ferretti, Virginia Valeria, additional, Rizzo, Ettore, additional, Varettoni, Marzia, additional, Frigeni, Marco, additional, Pulsoni, Alessandro, additional, Casato, Milvia, additional, Colantuono, Stefania, additional, Rossi, Marianna, additional, Candido, Chiara, additional, Zerbi, Caterina, additional, Bergamini, Fabio, additional, Cristinelli, Caterina, additional, Fabbri, Nicole, additional, Merli, Michele, additional, Zuccaro, Valentina, additional, Bruno, Raffaele, additional, Paulli, Marco, additional, and Arcaini, Luca, additional

Published
2021
Full Text
View/download PDF

12. Targeted next‐generation sequencing reveals molecular heterogeneity in non‐chronic lymphocytic leukemia clonal B‐cell lymphocytosis

Author

Defrancesco, Irene, primary, Zibellini, Silvia, additional, Boveri, Emanuela, additional, Frigeni, Marco, additional, Ferretti, Virginia Valeria, additional, Rizzo, Ettore, additional, Bonometti, Arturo, additional, Capuano, Francesca, additional, Candido, Chiara, additional, Rattotti, Sara, additional, Tenore, Annamaria, additional, Picone, Cristina, additional, Flospergher, Elena, additional, Zerbi, Caterina, additional, Bergamini, Fabio, additional, Fabbri, Nicole, additional, Cristinelli, Caterina, additional, Varettoni, Marzia, additional, Paulli, Marco, additional, and Arcaini, Luca, additional

Published
2020
Full Text
View/download PDF

13. Targeted Next Generation Sequencing Reveals Molecular Heterogeneity in Non-CLL Clonal B-Cell Lymphocytosis

Author

Defrancesco, Irene, primary, Zibellini, Silvia, additional, Boveri, Emanuela, additional, Frigeni, Marco, additional, Ferretti, Virginia Valeria, additional, Rizzo, Ettore, additional, Capuano, Francesca, additional, Bonometti, Arturo, additional, Candido, Chiara, additional, Rattotti, Sara, additional, Flospergher, Elena, additional, Bergamini, Fabio, additional, Zerbi, Caterina, additional, Paulli, Marco, additional, Varettoni, Marzia, additional, and Arcaini, Luca, additional

Published
2019
Full Text
View/download PDF

14. A risk‐stratification model based on the initial concentration of the serum monoclonal protein andMYD 88mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenström macroglobulinaemia or other lymphoproliferative disorders

Author

Varettoni, Marzia, primary, Zibellini, Silvia, additional, Boveri, Emanuela, additional, Klersy, Catherine, additional, Candido, Chiara, additional, Rattotti, Sara, additional, Ferretti, Virginia V., additional, Defrancesco, Irene, additional, Mangiacavalli, Silvia, additional, Nizzoli, Maria E., additional, Flospergher, Elena, additional, Zerbi, Caterina, additional, Bergamini, Fabio, additional, Benvenuti, Pietro, additional, Brociner, Marco, additional, Merati, Gabriele, additional, Paulli, Marco, additional, and Arcaini, Luca, additional

Published
2019
Full Text
View/download PDF

15. A risk‐stratification model based on the initial concentration of the serum monoclonal protein and MYD88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenström macroglobulinaemia or other lymphoproliferative disorders

Author

Varettoni, Marzia, Zibellini, Silvia, Boveri, Emanuela, Klersy, Catherine, Candido, Chiara, Rattotti, Sara, Ferretti, Virginia V., Defrancesco, Irene, Mangiacavalli, Silvia, Nizzoli, Maria E., Flospergher, Elena, Zerbi, Caterina, Bergamini, Fabio, Benvenuti, Pietro, Brociner, Marco, Merati, Gabriele, Paulli, Marco, and Arcaini, Luca

Subjects
MONOCLONAL gammopathies, LYMPHOPROLIFERATIVE disorders, BLOOD proteins, G proteins, DISEASE risk factors, CONFIDENCE intervals
Abstract

Summary: IgM monoclonal gammopathies of undetermined significance (IgM MGUS) are associated with a risk of progression to Waldenström macroglobulinaemia (WM) or other lymphoproliferative disorders (LPD) of 1–2% per year. We analysed 176 consecutive patients with IgM MGUS to evaluate risk factors for progression. With a median follow‐up of 83 months (1214 person‐years), 15 patients (8·5%) progressed to WM (n = 14) or marginal zone lymphoma (n = 1). The rate of progression was 1·32% per year (95% confidence interval [CI] 0·80–2·20). The serum monoclonal protein concentration and the MYD88 mutation were independent risk factors for progression (Hazard ratio [HR] 23·3, 95% CI 2·0–273·3, P = 0·012 and HR 24·4, 95% CI 2·2–275·3, P = 0·010, respectively). The cumulative incidence of progression, while considering death as a competing event, was 11·6% at 5 years and 38·0% at 10 years in MYD88‐mutated patients with a serum monoclonal protein of 10 g/l or higher, as compared with 0% at 5 years and 1·1% at 10 years for patients with none or one risk factor. This risk‐stratification model is able to identify a subset of patients with IgM MGUS at high risk of progression to WM or LPD who deserve a lifelong follow‐up. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

16. Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network.

Author

Rattotti, Sara, Ferretti, Virginia Valeria, Rusconi, Chiara, Rossi, Andrea, Fogazzi, Stefano, Baldini, Luca, Pioltelli, Pietro, Balzarotti, Monica, Farina, Lucia, Ferreri, Andrés J.M., Laszlo, Daniele, Speziale, Valentina, Varettoni, Marzia, Sciarra, Roberta, Morello, Lucia, Tedeschi, Alessandra, Frigeni, Marco, Defrancesco, Irene, Zerbi, Caterina, and Flospergher, Elena

Abstract

Chronic hepatitis C virus (HCV) infection is related with an increased risk of non-Hodgkin lymphomas (NHL). In indolent subtypes, regression of NHL was reported after HCV eradication with antiviral therapy (AT). In 2008 in Lombardy, a region of Northern Italy, the "Rete Ematologica Lombarda" (REL, Hematology Network of Lombardy-Lymphoma Workgroup) started a prospective multicenter observational cohort study on NHL associated with HCV infection, named "Registro Lombardo dei Linfomi HCV-positivi" ("Lombardy Registry of HCV-associated non-Hodgkin lymphomas"). Two hundred fifty patients with a first diagnosis of NHL associated with HCV infection were enrolled; also in our cohort, diffuse large B cell lymphoma (DLBCL) and marginal zone lymphoma (MZL) are the two most frequent HCV-associated lymphomas. Two thirds of patients had HCV-positivity detection before NHL; overall, NHL was diagnosed after a median time of 11 years since HCV survey. Our data on eradication of HCV infection were collected prior the recent introduction of the direct-acting antivirals (DAAs) therapy. Sixteen patients with indolent NHL treated with interferon-based AT as first line anti-lymphoma therapy, because of the absence of criteria for an immediate conventional treatment for lymphoma, had an overall response rate of 90%. After a median follow-up of 7 years, the overall survival (OS) was significantly longer in indolent NHL treated with AT as first line (P = 0.048); this confirms a favorable outcome in this subset. Liver toxicity was an important adverse event after a conventional treatment in 20% of all patients, in particular among DLBCL, in which it is more frequent the coexistence of a more advanced liver disease. Overall, HCV infection should be consider as an important co-pathology in the treatment of lymphomas and an interdisciplinary approach should be always considered, in particular to evaluate the presence of fibrosis or necroinflammatory liver disease. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

17. Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV

Author

Zappasodi P, Cattaneo C, Ferretti V, Mina R, Ferreri AJ, Merli F, Oberti M, Krampera M, Romano A, Zerbi C, Ferrari J, Cavo M, Marco Salvini M, Bertù L, Fracchiolla N, Marchesi F, Massaia M, Marasco V, Cairoli R, Scattolin AM, Vannucchi AM, Gambacorti-Passerini C, Musto P, Gherlinzoni F, Cuneo A, Pinto A, Trentin L, Bocchia M, Galimberti, Coviello E, Morotti A, Falini B, Turrin M, Tafuri A, Billio A, Gentile M, Lemoli M, Venditti A, Della Porta M, Lanza F, Rigacci L, Tosi P, Mohamed S, Corso A, Luppi M, Giuliani N, Busca A, Pagano L, Bruno R, Grossi P, Corradini P, Passamonti F, Arcaini L., Zappasodi, P, Cattaneo, C, Ferretti, V, Mina, R, Ferreri, A, Merli, F, Oberti, M, Krampera, M, Romano, A, Zerbi, C, Ferrari, J, Cavo, M, Marco Salvini, M, Bertù, L, Fracchiolla, N, Marchesi, F, Massaia, M, Marasco, V, Cairoli, R, Scattolin, A, Vannucchi, A, Gambacorti-Passerini, C, Musto, P, Gherlinzoni, F, Cuneo, A, Pinto, A, Trentin, L, Bocchia, M, Galimberti, Coviello, E, Mc, Morotti, A, Falini, B, Turrin, M, Tafuri, A, Billio, A, Gentile, M, Lemoli, M, Venditti, A, Della Porta, M, Lanza, F, Rigacci, L, Tosi, P, Mohamed, S, Corso, A, Luppi, M, Giuliani, N, Busca, A, Pagano, L, Bruno, R, Grossi, P, Corradini, P, Passamonti, F, Arcaini, L, Zappasodi, Patrizia, Cattaneo, Chiara, Ferretti, Virginia Valeria, Mina, Roberto, Ferreri, Andrés José María, Merli, Francesco, Oberti, Margherita, Krampera, Mauro, Romano, Alessandra, Zerbi, Caterina, Ferrari, Jacqueline, Cavo, Michele, Salvini, Marco, Bertù, Lorenza, Fracchiolla, Nicola Stefano, Marchesi, Francesco, Massaia, Massimo, Marasco, Vincenzo, Cairoli, Roberto, Scattolin, Anna Maria, Vannucchi, Alessandro Maria, Gambacorti-Passerini, Carlo, Musto, Pellegrino, Gherlinzoni, Filippo, Cuneo, Antonio, Pinto, Antonello, Trentin, Livio, Bocchia, Monica, Galimberti, Sara, Coviello, Elisa, Tisi, Maria Chiara, Morotti, Alessandro, Falini, Brunangelo, Turrini, Mauro, Tafuri, Agostino, Billio, Atto, Gentile, Massimo, Lemoli, Roberto Massimo, Venditti, Adriano, Della Porta, Matteo Giovanni, Lanza, Francesco, Rigacci, Luigi, Tosi, Patrizia, Mohamed, Sara, Corso, Alessandro, Luppi, Mario, Giuliani, Nicola, Busca, Alessandro, Pagano, Livio, Bruno, Raffaele, Grossi, Paolo Antonio, Corradini, Paolo, Passamonti, Francesco, and Arcaini, Luca

Subjects
Cancer Research, Lymphoma, Coinfection, COVID-19, Hematology, General Medicine, Settore MED/15, hematological malignancie, secondary infections, Settore MED/15 - MALATTIE DEL SANGUE, COVID-19 Testing, Oncology, Hematologic Neoplasms, secondary infection, outcome, Humans, hematological malignancies, Aged
Abstract

The impact of secondary infections (SI) on COVID-19 outcome in patients with hematological malignancies (HM) is scarcely documented. To evaluate incidence, clinical characteristics, and outcome of SI, we analyzed the microbiologically documented SI in a large multicenter cohort of adult HM patients with COVID-19. Among 1741 HM patients with COVID-19, 134 (7.7%) had 185 SI, with a 1-month cumulative incidence of 5%. Median time between COVID-19 diagnosis and SI was 16 days (IQR: 5-36). Acute myeloid leukemia (AML) and lymphoma/plasma cell neoplasms (PCN) were more frequent diagnoses in SI patients compared to patients without SI (AML: 14.9% vs. 7.1%; lymphoma/PCN 71.7% vs. 65.3%). Patients with SI were older (median age 70 vs. 66 years, p = 0.002), with more comorbidities (median Charlson Comorbidity Index 5 vs. 4, p < 0.001), higher frequency of critical COVID-19 (19.5% vs. 11.5%, p = 0.046), and more frequently not in complete remission (75% vs. 64.7% p = 0.024). Blood and bronchoalveolar lavage were the main sites of isolation for SI. Etiology of infections was bacterial in 80% (n = 148) of cases, mycotic in 9.7% (n = 18) and viral in 10.3% (n = 19); polymicrobial infections were observed in 24 patients (18%). Escherichia coli represented most of Gram-negative isolates (18.9%), while coagulase-negative Staphylococci were the most frequent among Gram-positive (14.2%). The 30-day mortality of patients with SI was higher when compared to patients without SI (69% vs. 15%, p < 0.001). The occurrence of SI worsened COVID-19 outcome in HM patients. Timely diagnosis and adequate management should be considered to improve their prognosis.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results